Treatment of primary central nervous system lymphoma in the immunocompetent patient

被引：2

作者：

Del Rio, M. Sierra ^{[1
]}

Benouaich-Amiel, A. ^{[1
]}

Psimaras, D. ^{[1
]}

Dehais, C. ^{[1
]}

Hoang-Xuan, K. ^{[1
]}

机构：

[1] CHU Pitie Salpetriere, Serv Neurol Mazarin, F-75651 Paris, France

来源：

REVUE NEUROLOGIQUE | 2008年 / 164卷 / 6-7期

关键词：

lymphoma; central nervous system; immunocompetent; steroids; radiotherapy; chemotherapy; methotrexate; neurotoxicity;

D O I：

10.1016/j.neurol.2008.04.001

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

The incidence of primary CNS lymphoma (PCNSL), which has considerably increased these last years, remains stable in the immunocompetent population, while it is steadily decreasing in the immunosuppressed population. The addition of high dose methotrexate (MTX) based chemotherapy (CT) before whole brain radiotherapy (WBRT) has clearly improved the prognosis of PCNSL with a median survival of three to four years. About 30% of the patients may hope to have a long survival and to be cured. in the elderly (age over 60 years) CT alone (without RT) is recommended as initial treatment. This approach seems useful to avoid RT and to reduce the risk of delayed neurotoxicity due to the combined treatment. in the young population (age less than 60 years), intensive chemotherapy followed by hematopoietic stem cell rescue (ICH) appears as a promising approach in recurrent tumors and potentially as an alternative option to RT as consolidation treatment in newly diagnosed patients. A prospective trial will be activated in France soon randomizing ICH and RT in the initial treatment of PCNSL. (C) 2008 Publie par Elsevier Masson SAS.

引用

页码：569 / 574

页数：6

共 45 条

[11] High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma [J].

Cheng, G ;

Forsyth, P ;

Chaudhry, A ;

Morris, D ;

Gluck, S ;

Russell, JA ;

Stewart, DA .

BONE MARROW TRANSPLANTATION, 2003, 31 (08) :679-685

[12] Therapy of primary CNS lymphoma with methotrexate-based chemotherapy and deferred radiotherapy: Preliminary results [J].

Cher, L ;

Glass, J ;

Harsh, GR ;

Hochberg, FH .

NEUROLOGY, 1996, 46 (06) :1757-1759

[13] High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years:: a multicenter phase II study ofthe GOELAMS group [J].

Colombat, Ph ;

Lemevel, A. ;

Bertrand, P. ;

Delwail, V. ;

Rachieru, P. ;

Brion, A. ;

Berthou, C. ;

Bay, J. O. ;

Delepine, R. ;

Desablens, B. ;

Camilleri-Broet, S. ;

Linassier, C. ;

Lamy, T. .

BONE MARROW TRANSPLANTATION, 2006, 38 (06) :417-420

[14]

Dahlborg S A, 1996, Cancer J Sci Am, V2, P166

[15] COMBINED MODALITY THERAPY FOR PRIMARY CNS LYMPHOMA [J].

DEANGELIS, LM ;

YAHALOM, J ;

THALER, HT ;

KHER, U .

JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (04) :635-643

[16] Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group study 93-10 [J].

DeAngelis, LM ;

Seiferheld, W ;

Schold, SC ;

Fisher, B ;

Schultz, CJ .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (24) :4643-4648

[17] Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients [J].

Freilich, RJ ;

Delattre, JY ;

Monjour, A ;

DeAngelis, LM .

NEUROLOGY, 1996, 46 (02) :435-439

[18] HIGH-DOSE METHOTREXATE FOR NON-AIDS PRIMARY CENTRAL NERVOUS-SYSTEM LYMPHOMA - REPORT OF 13 CASES [J].

GABBAI, AA ;

HOCHBERG, FH ;

LINGGOOD, RM ;

BASHIR, R ;

HOTLEMAN, K .

JOURNAL OF NEUROSURGERY, 1989, 70 (02) :190-194

[19]

Glass J, 1996, J NEURO-ONCOL, V30, P257

[20] PREIRRADIATION METHOTREXATE CHEMOTHERAPY OF PRIMARY CENTRAL-NERVOUS-SYSTEM LYMPHOMA - LONG-TERM OUTCOME [J].

GLASS, J ;

GRUBER, ML ;

CHER, L ;

HOCHBERG, FH .

JOURNAL OF NEUROSURGERY, 1994, 81 (02) :188-195

← 1 2 3 4 5 →